Navigation

TA143 Adalimumab, etanercept ac infliximab ar gyfer spondylitis ymasiol: deall canllawiau NICE (fformat MS Word)

The summary of the key recommendations of the technology appraisal on Ankylosing spondylitis - adalimumab, etanercept and infliximab. It is written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets or any other suitable publication.

This page was last updated: 30 March 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.